TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05445466

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Definition Transcranial Electrical-Current Stimulation
Description: Non-frequency dependent transcranial electrical stimulation condition for 5 days of twice a day treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-Definition Transcranial Alternate-Current Stimulation
Description: Active-control stimulation condition will target alpha (10 Hz) for 5 days of twice a day treatment
Study: NCT05499429

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial low intensity focused ultrasound stimulation
Description: Low intensity focused transcranial ultrasound stimulation can safely and effectively regulate neuron excitability through mechanical force.
Study: NCT05428735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: Portal Vein embolization with Glue by a transhepatic approach vs. PVE and Hepatic Vein Occlusion with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embolization
Description: Portal Vein embolization with Glue by a transhepatic approach vs. PVE and Hepatic Vein Occlusion with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure
Study: NCT05080400

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White rice
Description: Jasmine rice 179g of cooked weight

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White rice
Description: Jasmine rice 179g of cooked weight

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gellan gum
Description: Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
Study: NCT05445466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Definition Personalized Beta-Gamma Electrical Stimulation
Description: Personalized beta-gamma electrical stimulation for 5 days of twice a day treatment
Study: NCT04755322

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400 mg at start of pregnancy

Intervention type: DRUG
Group type: OTHER
Intervention: Folic acid
Description: 5 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Folic acid
Description: 5 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Low-dose aspirin
Description: 75 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Low-dose aspirin
Description: 75 mg
Study: NCT05107609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute Self-Compassion Intervention
Description: Participants will be guided through a 30-minute behavioural self-compassion intervention that seeks to mitigate their psychobiological responses to the subsequent weight stigma induction. The intervention is intended to induce a flexible self-compassionate mindset that will facilitate more adaptive psychological responding to stress and activate affiliative/self-soothing physiological systems that can dampen psychobiological stress reactivity. This acute self-compassion intervention will employ a multimodal, experiential approach that is regularly utilized in self-compassion training, drawing from approaches developed in Compassion-Focused Therapy and Mindful Self-Compassion.
Study: NCT06126042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: DRL_AB, Pre Filled Syringe; Solution for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product
Description: USA licenced ORENCIA®, Pre Filled Syringe; Solution for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Medicinal Product
Description: EU approved ORENCIA®, Pre Filled Syringe; Solution for injection
Study: NCT05505734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDA MDI
Description: Participants will receive Budesonide and Albuterol Sulfate MDI 80/90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS MDI
Description: Participants will receive Albuterol Sulfate MDI 90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
Study: NCT05088928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Direct Acting Oral Anti coagulant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Direct Acting Oral Anti coagulant
Study: NCT04290221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous electrolysis in the lumbar nerve root
Description: This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3 (one times per week / 3 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Dry Needling in trigger points
Description: It consists in apply the ultrasound-guided percutaneous electrolysis on active and/or latent TPs in the gluteus medius, quadratus lumborum, and erector spinae muscles of the subjects L3 (one times per week / 6 weeks).
Study: NCT05111912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XW003
Description: XW003 (from 0.2 mg to 1.2 mg, 1.8 mg, and 2.4 mg once weekly), should take place during the first 14 weeks after randomization as described: Dose Escalation Schedule of Investigational Product (XW003). All eligible participants assigned to the XW003 study groups should aim to reach the respective final target dose of XW003 at 1.2 mg, 1.8 mg, or 2.4 mg once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XW003
Description: XW003 (from 0.2 mg to 1.2 mg, 1.8 mg, and 2.4 mg once weekly), should take place during the first 14 weeks after randomization as described: Dose Escalation Schedule of Investigational Product (XW003). All eligible participants assigned to the XW003 study groups should aim to reach the respective final target dose of XW003 at 1.2 mg, 1.8 mg, or 2.4 mg once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XW003
Description: XW003 (from 0.2 mg to 1.2 mg, 1.8 mg, and 2.4 mg once weekly), should take place during the first 14 weeks after randomization as described: Dose Escalation Schedule of Investigational Product (XW003). All eligible participants assigned to the XW003 study groups should aim to reach the respective final target dose of XW003 at 1.2 mg, 1.8 mg, or 2.4 mg once weekly.
Study: NCT05627180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Health Literacy follow-up in cancer
Description: 1. Participants are invited to a consultation with the project nurse where the project nurse will use baseline data to identify the patient's HL needs, QOL, symptom burden and issues related to self-management of their cancer and treatment. These data will be used together with an interview questionnaire specifically developed to communicate HL needs (i.e. CHAT), which form the basis for the individualized HL support.~2. Actions: Based on results of the consultation, the project nurse and the patient will use a worksheet of possible actions to identify those most relevant to the patient's individual needs. Based on this, different self-management tasks and actions will be offered, and an individual tailored follow-up plan will be made. The patient and the project nurse will use a workbook containing information on the follow-up plan that will be added into medical record.~3. Telephone/digital conversations with the project every second month for a period of 9 months.
Study: NCT06484595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive SOC supportive care services

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive SOC supportive care services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Receive clinical trial navigator guide services
Study: NCT06277388

Intervention type: DEVICE
Intervention: Impedance cardiography
Description: The study conducted a 6-minute walk test (6MWT) in a hospital hallway following ATS guidelines. Patients rested for 10 minutes before the test. Impedance measurements were taken before (2 minutes), during (6 minutes), and after (3 minutes) the walk, recording cardio-dynamic parameters with impedance cardiography (ICG).
Study: NCT03941860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT06528574

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional root canal treatment
Description: Root canals will be irrigated by only side perforated needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic
Description: Root canals will finally receive activation of the irrigant by the ultrasonic part of the IVAC system
Study: NCT03941860

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06528574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apical negative pressure
Description: Root canals will finally receive activation of the irrigant by the negative pressure part of the IVAC system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Ultrasonic and negative pressure
Description: Root canals will finally receive activation of the irrigant by the IVAC system which is a combination of ultrasonic and apical negative pressure procedures.
Study: NCT03941860

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05803278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online enhancement training
Description: Online enhancement training lasting 3 months, using the InTempo app system (Gea-Metaphonology-Athena-reading/Ermes-writing) three times a week for twenty minutes. The training will include: Metaphonological Enhancement; Reading Enhancement; Writing Enhancement.
Study: NCT03941860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05080803

Intervention type: DRUG
Intervention: intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone
Description: intravitreal administration

Intervention type: DRUG
Intervention: intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone
Description: intravitreal administration

Intervention type: DRUG
Intervention: intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone
Description: intravitreal administration

Intervention type: DRUG
Intervention: intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone
Description: intravitreal administration
Study: NCT05364541

Intervention type: DEVICE
Group type: OTHER
Intervention: MyoVista wavECG
Description: A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.
Study: NCT04879875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IscAlert
Description: 3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed after end of surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IscAlert 72h
Description: 3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed 72 hours after end of surgery
Study: NCT05859204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OT-led Exercise Group
Description: Participants will complete pre-intervention self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin 10-minute educational session that describes the purpose of the exercise intervention and methods to remain safe during the intervention such as self-monitoring techniques. Following completion of the educational session, participants will complete a 30-minute exercise intervention under the guidance of the OT, which includes warm-up, high intensity interval training cardio, strength, kick boxing, cool-down, and yoga. Following completion of the exercise regimen, participants will participate in a 10-minute discussion and reflection with the OT and complete post-intervention self-report surveys. Participants in the intervention arm will also receive routine daily occupational therapy educational sessions received by the treatment as usual arm.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual - OT Groups
Description: Participants will complete pre-session self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin daily educational session about the topic of choice for that day. Treatment groups are largely discussion-based and include the following topics: coping skills, self-esteem, sleep management, leisure, time management, life skills, decision making, and goal setting. Following completion of the educational session, participants will complete post-intervention self-report surveys.
Study: NCT06187753

Intervention type: DIAGNOSTIC_TEST
Intervention: Sensory Profile
Description: The Sensory Profile has 125 items that represent 14 functions of sensory processing and allows parents to report on their child's behavior.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sensory Profile
Description: The Sensory Profile has 125 items that represent 14 functions of sensory processing and allows parents to report on their child's behavior.
Study: NCT05214807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KiOmedine® CM-Chitosan
Description: KiOmedine® CM-Chitosan is a fluid implant intended for synovial fluid supplementation for the symptomatic treatment of osteoarthritis (OA). This Investigational Medical Device (IMD) is administered via intra-articular injection and is classified as a Class III Device under Council Directive 93/42/EEC (Annex IX, rule 8). A key component of the IMD is a soluble derivative of highly purified chitosan of non-animal origin, an exclusive natural linear glucosamine polysaccharide extracted from the edible white mushroom, Agaricus bisporus. KiOmedine® CM-Chitosan is sterile, non-pyrogenic, resorbable and composed of 2% (w:w) carboxymethyl chitosan (CM-chitosan).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One®
Description: Synvisc-One (Hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing Hylan A and Hylan B polymers produced from chicken combs. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. Hylan A has an average molecular weight of approximately 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains Hylan A and Hylan B (8.0 mg ± 2.0 mg per ml) in buffered physiological sodium chloride solution (pH 7.2 ± 0.3) and is unique in that the hyaluronan is chemically crosslinked.
Study: NCT05687305

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Noise
Description: White noise is produced by digitally combining sounds of equal frequency in the laboratory. Then, all of the frequencies in this sound are calibrated to generate noise at each frequency. If the contribution of each region to the noise level is the same, the noise is referred to as white noise. Waterfalls, ocean waves, and wind blowing through trees all produce similar to white noise. Patients in the intervention group are observed by the investigator on the 0th and 1st postoperative days.Before going to sleep, a bluetooth headset will be used to listen to white noise for 30 minutes and vital signs will be measured before and after the procedure.
Study: NCT06113523

Intervention type: BIOLOGICAL
Intervention: monogenic obesity
Description: The DNA samples will be sequenced for the 71 obesity genes especially for the study.
Study: NCT04938778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: PNF Participants will engage in 8 weeks of 14 hours per night fasting
Study: NCT04902807

Intervention type: BIOLOGICAL
Intervention: Collection of samples
Description: Blood, Urine and Stool samples will be collected from the participants.

Intervention type: BIOLOGICAL
Intervention: Collection of samples
Description: Blood, Urine and Stool samples will be collected from the participants.

Intervention type: BIOLOGICAL
Intervention: Collection of samples
Description: Blood, Urine and Stool samples will be collected from the participants.
Study: NCT05760079

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: 750mg of Jarrow formulas taken three times daily for 30 days
Study: NCT06226454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.
Study: NCT05111912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxenda
Description: If a participant does not tolerate the recommended target dose of Saxenda group (e.g., 3.0 mg once daily), the participant may stay at the preceding highest tolerable dose (e.g., 2.4 mg once daily).
Study: NCT05644626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-B167
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-B167
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Intravenous administration
Study: NCT05131217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute bout of Continuous Moderate Intensity Exercise
Description: In this experimental intervention subjects will cycle continuously at moderate intensity (VO2 corresponding to lactate threshold) until a 200 kcal equivalent energy expenditure is reached.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute bout of High Intensity Interval Training
Description: In this experimental invention subjects will alternate between 1 minute of high intensity cycling (watts corresponding to 85% VO2peak) and 1 minute of low intensity cycling (watts corresponding to 35-40% VO2peak) until a 200 kcal equivalent energy expenditure is reached.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: In this intervention placebo, subjects will lay down on a flat, soft surface for 30 minutes in a dimly light room. They will not be allowed to use any electronic devices or read during this time to avoid potentially influencing continuous data recording.
Study: NCT05374122

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DSOC with AI biopsy guidance
Description: Patients with a presumptive diagnosis of biliary malignancy will undergo DSOC + Artificial intelligence model (AIWorks) guidance for detection of neoplastic lesion during real-time procedure, tissue sampling acquisition, and histopathological analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: DSOC biopsy without AI guidance
Description: Patients with lesions suggestive of malignancy will undergo DSOC without AI guidance for sampling.~Based on the observer´s criteria regarding areas suggestive of malignancy, the collected tissue sample will be sent for histopathological studies.
Study: NCT06142487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silk Pillowcase
Description: 100% Mulberry Silk Pillowcase

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cotton Pillowcase
Description: 100% Cotton Pillowcase